


Ask a doctor about a prescription for TELMISARTAN/HYDROCHLOROTHIAZIDE STADA 40 mg/12.5 mg TABLETS
Package Leaflet: Information for theuser
Telmisartan/HydrochlorothiazideStada40 mg/12.5 mg tablets EFG
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the packand other information
Telmisartan/Hydrochlorothiazide is a combination of two active substances, telmisartan and hydrochlorothiazide, in one tablet. Both active substances help to control high blood pressure.
Telmisartan/Hydrochlorothiazide is usedto treat high blood pressure (essential hypertension) in adults whose blood pressure is not adequately controlled when using telmisartan alone.
If any of the above applies to you, inform your doctor or pharmacist before using telmisartan/hydrochlorothiazide.
Warnings and precautions
Consult your doctor if you have or have had any of the following disorders or diseases:
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking telmisartan/hydrochlorothiazide. Your doctor will decide whether to continue treatment. Do not stop taking telmisartan/hydrochlorothiazide on your own.
Consult your doctor, pharmacist, or nurse before starting to take telmisartan/hydrochlorothiazide
Your doctor may check your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals. See also the information under the heading "Do not take Telmisartan/Hydrochlorothiazide Stada".
If you are pregnant (or think you may be), inform your doctor. Telmisartan/hydrochlorothiazide is not recommended during pregnancy and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby.
Treatment with hydrochlorothiazide can cause an electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, somnolence, restlessness, pain or muscle cramps, nausea, vomiting, muscle fatigue, and an abnormally fast heart rate (more than 100 beats per minute). If you experience any of these symptoms, inform your doctor.
You should also inform your doctor if you experience increased skin sensitivity to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) that appear more quickly than usual.
If you are going to have surgery or anesthesia, inform your doctor that you are taking telmisartan/hydrochlorothiazide.
Telmisartan/hydrochlorothiazide may be less effective in lowering blood pressure in black patients.
Children and adolescents
The use of telmisartan/hydrochlorothiazide is not recommended in children and adolescents up to 18 years of age.
Athletes
Athletes are informed that this medicine contains a component that may result in a positive doping test.
Other medicines and Telmisartan/Hydrochlorothiazide Stada
Inform your doctor or pharmacist if you are using, have recently used, or might use any other medicines, including those without a prescription. Your doctor may need to modify your dose and/or take other precautions. In some cases, it may be necessary to interrupt the use of some of these medicines, especially if you are using telmisartan/hydrochlorothiazide with any of the following medicines:
Telmisartan/hydrochlorothiazide may increase the ability of other medicines to lower blood pressure or medicines that can potentially lower blood pressure (e.g., baclofen, amifostine). Additionally, the decrease in blood pressure may be enhanced by alcohol, barbiturates, narcotics, or antidepressants. You may notice this effect as dizziness when standing up. You should inform your doctor about the need to adjust the dose of your other medicines while taking telmisartan/hydrochlorothiazide.
The effect of telmisartan/hydrochlorothiazide may be reduced when using non-steroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin or ibuprofen).
Taking Telmisartan/Hydrochlorothiazide Stada with food and alcohol
You can take this medicine with or without food.
Avoid drinking alcohol until you have talked to your doctor. Alcohol can further lower your blood pressure and/or increase the risk of feeling dizzy or weak.
Pregnancy and breastfeeding
Pregnancy
You should inform your doctor if you are pregnant (or think you may be). Your doctor will usually advise you to stop taking telmisartan/hydrochlorothiazide before you become pregnant or as soon as you find out you are pregnant, and recommend that you take another blood pressure-lowering medicine instead. Telmisartan/hydrochlorothiazide is not recommended during pregnancy and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby.
Breastfeeding
Inform your doctor if you are about to start or are breastfeeding. Telmisartan/hydrochlorothiazide is not recommended for use in women during breastfeeding, as your doctor may decide to give you a treatment that is more suitable if you want to breastfeed.
Driving and using machines
Some patients feel dizzy or tired when taking telmisartan/hydrochlorothiazide. If you feel dizzy or tired, do not drive or use machines.
Telmisartan/Hydrochlorothiazide Stadacontains lactose and sodium
If your doctor has told you that you have an intolerance to some sugars, consult with them before using this medicine.
This medicine contains less than 23 mg of sodium (1 mmol); this is essentially "sodium-free".
Follow exactly the instructions of administration of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
The recommended dose of telmisartan/hydrochlorothiazide is one tablet per day. Try to take one tablet each day at the same time. You can take telmisartan/hydrochlorothiazide with or without food. The tablets should be swallowed with a little water or other non-alcoholic drink. It is important that you take telmisartan/hydrochlorothiazide every day until your doctor tells you to stop.
If your liver is not working properly, the usual dose should not exceed 40 mg/12.5 mg once a day.
If you take more Telmisartan/Hydrochlorothiazide Stada than you should
If you accidentally take too many tablets, you may experience symptoms such as low blood pressure and rapid heartbeat. Slow heartbeat, dizziness, vomiting, and reduced kidney function, including kidney failure, have also been reported. Due to the hydrochlorothiazide component, you may also experience significantly low blood pressure and low potassium levels in the blood, which can lead to nausea, somnolence, and muscle cramps and/or irregular heartbeats associated with concomitant use of medicines like digitalis or certain antiarrhythmic treatments. Contact your doctor or pharmacist or the nearest hospital emergency department immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Telmisartan/Hydrochlorothiazide Stada
If you forget to take your medicine, do not worry. Take the dose as soon as you remember and continue as before. If you do not take your tablet one day, take your normal dose the next day. Do not takea double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Some adverse effects can be serious and require immediate medical attention:
If you experience any of the following symptoms, you should visit your doctor immediately:
Sepsis* (often called "blood infection"), is a serious infection that involves an inflammatory reaction of the entire body, rapid swelling of the skin and mucous membranes (angioedema), blistering and peeling of the skin and mucous membranes (toxic epidermal necrolysis); these adverse effects are rare (may affect up to 1 in 1,000 people) or of unknown frequency (toxic epidermal necrolysis) but are extremely serious and patients should stop taking the medicine and visit their doctor immediately. If these adverse effects are not treated, they can be fatal. An increase in the incidence of sepsis with telmisartan alone has been observed; however, it cannot be ruled out for telmisartan/hydrochlorothiazide.
Possible Adverse Effects of Telmisartan/Hydrochlorothiazide Stada:
Frequent Adverse Effects (may affect up to 1 in 10 people):
Dizziness.
Uncommon Adverse Effects (may affect up to 1 in 100 people):
Decrease in potassium levels in the blood, anxiety, fainting (syncope), tingling sensation, numbness (paresthesia), dizziness (vertigo), rapid heartbeat (tachycardia), heart rhythm disturbances, low blood pressure, sudden drop in blood pressure when standing up, shortness of breath (dyspnea), diarrhea, dry mouth, flatulence, back pain, muscle spasms, muscle pain, erectile dysfunction (inability to have or maintain an erection), chest pain, and increased uric acid levels in the blood.
Rare Adverse Effects (may affect up to 1 in 1,000 people):
Lung inflammation (bronchitis), activation or worsening of systemic lupus erythematosus (a disease in which the body's immune system attacks the body, causing joint pain, skin rashes, and fever), sore throat, sinus inflammation, feeling of sadness (depression), difficulty falling asleep (insomnia), vision disturbances, breathing difficulties, abdominal pain, constipation, abdominal distension (dyspepsia), general malaise (vomiting), stomach inflammation (gastritis), alteration in liver function (Japanese patients show a greater tendency to experience this adverse effect), rapid swelling of the skin and mucous membranes that can be life-threatening (angioedema, including fatal outcome), skin redness (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia), and pain in the limbs, muscle cramps, pseudogrippal illness, pain, increased uric acid levels, low sodium levels, increased creatinine, liver enzymes, or creatine phosphokinase levels in the blood.
Adverse reactions reported for one of the individual components may be potential adverse reactions of telmisartan/hydrochlorothiazide, even if they have not been observed in clinical trials with this product.
Telmisartan
The following additional adverse effects have been reported in patients taking telmisartan alone:
Uncommon Adverse Effects (may affect up to 1 in 100 people):
Upper respiratory tract infection (e.g., sore throat, sinusitis, common cold), urinary tract infections, red blood cell deficiency (anemia), high potassium levels, slow heart rate (bradycardia), cough, alteration in kidney function, including acute kidney failure, weakness.
Rare Adverse Effects (may affect up to 1 in 1,000 people):
Low platelet count (thrombocytopenia), increase in certain white blood cells (eosinophilia), severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions, drug rash), low blood sugar levels (in diabetic patients), drowsiness, stomach discomfort, eczema (a skin disorder), osteoarthritis, tendon inflammation, decrease in hemoglobin (a blood protein).
Very Rare Adverse Effects (may affect up to 1 in 10,000 people):
Progressive fibrosis of lung tissue (interstitial lung disease) **
Frequency Not Known (frequency cannot be estimated from available data):
Intestinal angioedema: inflammation in the intestine has been reported, presenting symptoms such as abdominal pain, nausea, vomiting, and diarrhea after using similar products.
** Cases of progressive fibrosis of lung tissue have been reported during telmisartan treatment. However, it is unknown whether telmisartan was the cause.
Hydrochlorothiazide
The following additional adverse effects have been reported in patients taking hydrochlorothiazide alone:
Frequent Adverse Effects (may affect up to 1 in 10 people):
Nausea, low magnesium level in the blood.
Rare Adverse Effects (may affect up to 1 in 1,000 people):
Decrease in platelet count in the blood, which increases the risk of bleeding and bruising (small purple-red spots on the skin or other tissues caused by bleeding), high calcium level in the blood, headache.
Very Rare Adverse Effects (may affect up to 1 in 10,000 people):
Increased pH (acid-base imbalance) due to low chloride level in the blood, acute respiratory distress (signs include severe respiratory distress, fever, weakness, and confusion).
Frequency Not Known (cannot be estimated from available data):
Salivary gland inflammation, skin and lip cancer (non-melanoma skin cancer), decrease in blood cell count, including low red and white blood cell count, severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions), decreased or lost appetite, restlessness, dizziness, blurred or yellowish vision, decreased vision, and eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma), blood vessel inflammation (necrotizing vasculitis), pancreatitis, stomach discomfort, yellowing of the skin or eyes (jaundice), pseudolupus syndrome (a condition that mimics systemic lupus erythematosus, in which the body's immune system attacks the body), skin disorders such as blood vessel inflammation of the skin, increased sensitivity to sunlight, skin rash, skin redness, blistering of the lips, eyes, or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney inflammation or altered function, glucose in the urine (glucosuria), fever, electrolyte imbalance, high cholesterol levels in the blood, decreased blood volume, increased glucose levels in the blood, difficulty controlling blood sugar levels in patients with diabetes mellitus, or fat in the blood.
If you experience adverse effects, consult your doctor or pharmacist, even if they are not listed in this leaflet.
Reporting Adverse Effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them through the Spanish Pharmacovigilance System for Human Use Medicines. https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require any special storage temperature. Store in the original packaging to protect it from light and moisture. Remove your telmisartan/hydrochlorothiazide tablet just before taking it.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the pharmacy's SIGRE point. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Telmisartan/Hydrochlorothiazide Stada
Appearance and Package Contents
Telmisartan/Hydrochlorothiazide Stada 40 mg/12.5 mg tablets are round, biconvex, white and yellow tablets.
Telmisartan/Hydrochlorothiazide Stada is available in blister packs containing 7, 10, 14, 28, 28x1, 30, 30x1, 50, 56, 84, 90, 90x1, 98, 100, 112, 126, 140, 154, 168, 182, or 196 tablets.
Not all pack sizes may be marketed in your country.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer
Liconsa, S.A.
Avda. Miralcampo, nº 7,
Polígono Industrial Miralcampo 19200 Azuqueca de Henares (Guadalajara)
Spain
or
Medical Valley Invest AB
Bradgardsvagen 28 2 Tr
236 32 Höllviken
Sweden
Date of Last Revision of this Leaflet: February 2025
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of TELMISARTAN/HYDROCHLOROTHIAZIDE STADA 40 mg/12.5 mg TABLETS in November, 2025 is around 9.68 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TELMISARTAN/HYDROCHLOROTHIAZIDE STADA 40 mg/12.5 mg TABLETS – subject to medical assessment and local rules.